• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    11/14/24 12:15:08 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERA alert in real time by email
    SC 13G/A 1 veraa2_111424.htm KYNAM CAPITAL MANAGEMENT, LP veraa2_111424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Vera Therapeutics, Inc.
    (Name of Issuer)
    Class A common stock, $0.001 par value per share
    (Title of Class of Securities)
    92337R101
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 92337R101
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3660072
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    1,576,549
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    1,576,549
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,576,549
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.49%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 92337R101
           
    1
    NAME OF REPORTING PERSON
    Kynam Capital Management GP, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    85-3678691
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    1,576,549
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    1,576,549
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,576,549
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.49%
    12
    TYPE OF REPORTING PERSON
    OO
    CUSIP No.: 92337R101
           
    1
    NAME OF REPORTING PERSON
    Yue Tang
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    1,576,549
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    1,576,549
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.49%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 92337R101
    ITEM 1(a). NAME OF ISSUER:
    Vera Therapeutics, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    2000 Sierra Point Parkway, Suite 1200
    Brisbane, CA USA
    94005
    ITEM 2(a). NAME OF PERSON FILING:
    Kynam Capital Management, LP
    Kynam Capital Management GP, LLC
    Yue Tang
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    221 Elm Road. Princeton, NJ 08540
    ITEM 2(c). CITIZENSHIP:
    Delaware
    Delaware
    U.S.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Class A common stock, $0.001 par value per share
    ITEM 2(e). CUSIP NUMBER:
    92337R101
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    1,576,549
    (b) Percent of class:
    2.49%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (ii) shared power to vote or to direct the vote:
    Kynam Capital Management, LP : 1,576,549

    Kynam Capital Management GP, LLC : 1,576,549

    Yue Tang : 1,576,549
    (iii) sole power to dispose or direct the disposition of:
    Kynam Capital Management, LP :

    Kynam Capital Management GP, LLC :

    Yue Tang :
    (iv) shared power to dispose or to direct the disposition of:
    Kynam Capital Management, LP : 1,576,549

    Kynam Capital Management GP, LLC : 1,576,549

    Yue Tang : 1,576,549
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 92337R101
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14 2024
    Kynam Capital Management, LP By: Kynam Capital Management GP, LLC, its General Partner
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    November 14 2024
    Kynam Capital Management GP, LLC
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Managing Member
    November 14 2024
    Yue Tang
    By:
    /s/ Yue Tang
    Name:
    Yue Tang
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $VERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERA

    DatePrice TargetRatingAnalyst
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    1/8/2024Overweight
    Cantor Fitzgerald
    12/18/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025Expanded atacicept development program across multiple autoimmune kidney diseases is underway BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March

      5/6/25 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on April 3, 2025 has an exercise price per share equal to $22.74, Vera's closing trading price on April

      4/9/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

      On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN). "We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing

      4/3/25 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Vera Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00

      5/5/25 9:37:24 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Vera Therapeutics with a new price target

      Wolfe Research initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $49.00

      2/4/25 7:12:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vera Therapeutics with a new price target

      Goldman initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $58.00

      1/28/25 8:54:12 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:10:28 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:05:17 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vera Therapeutics Inc.

      SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 1:22:39 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

      BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

      11/18/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

      BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

      7/1/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

      BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be

      6/11/24 4:01:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/1/24 5:58:54 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    SEC Filings

    See more
    • Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      5/6/25 8:00:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Vera Therapeutics Inc.

      DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)

      4/3/25 4:08:41 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Vera Therapeutics Inc.

      DEF 14A - Vera Therapeutics, Inc. (0001831828) (Filer)

      4/3/25 4:06:57 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Financials

    Live finance-specific insights

    See more
    • Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

      BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre

      1/13/25 7:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

      New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

      6/17/23 10:10:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

      Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)

      1/30/23 6:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Fordyce Marshall sold $546,914 worth of shares (19,688 units at $27.78), decreasing direct ownership by 9% to 204,665 units (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/27/25 4:05:29 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R was granted 10,740 shares, increasing direct ownership by 21% to 61,946 units (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/20/25 4:13:15 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Turner William D. was granted 22,500 shares (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/20/25 4:11:50 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care